Is BAYZF.PK a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

417 people get BAYZF.PK articles and Market Currents by email alert.

Get email alerts on BAYZF.PK »

HEADLINES:

Bayer Offers Shareholders In Conceptus An Excellent Exit Opportunity
The Value Investor • Thu, May 2
Wall Street Breakfast: Must-Know News
Wall Street Breakfast • Mon, Apr 29 • 48 Comments
DAX Will Reflect German Economic Power In The EU
Vinayak Maheswaran • Thu, Feb 28
China Biotech Week In Review: Regeneron Pharma, Bayer Start New Trial For DME Treatment
ChinaBio Today • Sun, Feb 24
Wall Street Breakfast: Must-Know News
Wall Street Breakfast • Wed, Jan 23 • 116 Comments
Wall Street Breakfast: Must-Know News
Wall Street Breakfast • Thu, Jan 17 • 139 Comments
Muscle Pharm Corporation: Potential For A Multi-Bagger If Cost Structure Is Addressed
Devon Shire • Wed, Jan 2 • 9 Comments
Trius: The Winner In The War Against MRSA
Suresh Gupta • Tue, Dec 11, 2012 • 1 Comment
Wall Street Breakfast: Must-Know News
Wall Street Breakfast • Tue, Oct 30, 2012 • 97 Comments
Regeneron Pharmaceuticals: A Biotech Heading To $200
Drug Dates • Wed, Sep 19, 2012 • 4 Comments
Consider These Big Pharma Stocks Instead Of Novartis
Mel Daris • Tue, Sep 11, 2012 • 2 Comments
Revamped Europe ETF Hedges Euro Currency Risks
Tom Lydon • Thu, Sep 6, 2012
Disruptive Biotechnologies Stir Up Profits: Ray Blanco
Life Sciences Report • Mon, Aug 6, 2012 • 4 Comments
Onyx Pharmaceuticals' Shorts Appear Focused On Upcoming FDA Review Of Drug
Brian L. Wilson • Wed, Jun 20, 2012 • 1 Comment
3 Reasons To Buy Onyx Pharmaceuticals
Markus Aarnio • Sun, May 27, 2012
Maxygen: Bayer $30 Million Payment Likely In 2012
Apsara Biotechnology Research • Wed, May 2, 2012
Why Trius Therapeutics Is A Gem In The Innovative Antibiotics Market
John Eastman • Fri, Apr 13, 2012 • 1 Comment
Cashing In On Diabetes: The Race To The Artificial Pancreas
Jessica King Holden • Wed, Mar 7, 2012 • 5 Comments
IPO Preview: Cempra Holdings
IPOdesktop • Wed, Feb 1, 2012 • 1 Comment
Trius Therapeutics: Weakness Presents Opportunity
ScriptVolume • Fri, Jan 27, 2012 • 2 Comments

To learn more about Seeking Alpha Pro, click here.

There are no Focus articles on BAYZF.PK.

Bayer Offers Shareholders In Conceptus An Excellent Exit Opportunity
The Value Investor • Thu, May 2
Wall Street Breakfast: Must-Know News
Wall Street Breakfast • Mon, Apr 29 • 48 Comments
DAX Will Reflect German Economic Power In The EU
Vinayak Maheswaran • Thu, Feb 28
China Biotech Week In Review: Regeneron Pharma, Bayer Start New Trial For DME Treatment
ChinaBio Today • Sun, Feb 24
Wall Street Breakfast: Must-Know News
Wall Street Breakfast • Wed, Jan 23 • 116 Comments
Wall Street Breakfast: Must-Know News
Wall Street Breakfast • Thu, Jan 17 • 139 Comments
Muscle Pharm Corporation: Potential For A Multi-Bagger If Cost Structure Is Addressed
Devon Shire • Wed, Jan 2 • 9 Comments
Trius: The Winner In The War Against MRSA
Suresh Gupta • Tue, Dec 11, 2012 • 1 Comment
Wall Street Breakfast: Must-Know News
Wall Street Breakfast • Tue, Oct 30, 2012 • 97 Comments
Regeneron Pharmaceuticals: A Biotech Heading To $200
Drug Dates • Wed, Sep 19, 2012 • 4 Comments
Consider These Big Pharma Stocks Instead Of Novartis
Mel Daris • Tue, Sep 11, 2012 • 2 Comments
Revamped Europe ETF Hedges Euro Currency Risks
Tom Lydon • Thu, Sep 6, 2012
Disruptive Biotechnologies Stir Up Profits: Ray Blanco
Life Sciences Report • Mon, Aug 6, 2012 • 4 Comments
Onyx Pharmaceuticals' Shorts Appear Focused On Upcoming FDA Review Of Drug
Brian L. Wilson • Wed, Jun 20, 2012 • 1 Comment
3 Reasons To Buy Onyx Pharmaceuticals
Markus Aarnio • Sun, May 27, 2012
Maxygen: Bayer $30 Million Payment Likely In 2012
Apsara Biotechnology Research • Wed, May 2, 2012
Why Trius Therapeutics Is A Gem In The Innovative Antibiotics Market
John Eastman • Fri, Apr 13, 2012 • 1 Comment
Cashing In On Diabetes: The Race To The Artificial Pancreas
Jessica King Holden • Wed, Mar 7, 2012 • 5 Comments
IPO Preview: Cempra Holdings
IPOdesktop • Wed, Feb 1, 2012 • 1 Comment
Trius Therapeutics: Weakness Presents Opportunity
ScriptVolume • Fri, Jan 27, 2012 • 2 Comments

There are no Transcripts on BAYZF.PK.

There are no News articles on BAYZF.PK.

BAYZF.PK vs. ETF Alternatives

Company Description

Currently, there's no company description for BAYZF.PK.

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Monday, April 29, 5:32 AM Bayer AG (BAYZF.PK) says it will acquire Conceptus (CPTS) for $1.1B in a deal that will pay CPTS shareholders $31 per share in cash, a near 20% premium to Friday's close. With the deal, Bayer gets CPTS' surgery free, permanent birth control method, expanding its portfolio of contraceptive offerings. Comment! [M&A, Healthcare]
Tuesday, April 16, 4:44 PM Actavis (ACT) rallies +1% into the close after an appeals court rules in the company's favor regarding a patent dispute with Bayer (BAYZF.PK). Actavis yanked its generic version of the contraceptive Yaz from pharmacies last year after Bayer successfully challenged it on patent infringement grounds in a Nevada court. Comment! [Healthcare]
Thursday, February 28, 8:24 AM Bayer (BAYZF.PK): Q4 net profit slips 5.8% to €374M. Adjusted EPS €1 vs €0.97. Underlying EBITDA +18.4% to €1.83B, in line. Revenue +7.3% to €9.86B, slightly above consensus. Expects 2013 underlying EBITDA growth in the mid-single-digits vs forecasts of 8%, and for adjusted EPS to increase by high-single-digits. Forecasts annual sales of over €2.5B for five key drugs by 2015, which is better than previously expected. Shares +1.8% to €75.40 in Frankfurt. (PR) Comment! [Earnings, Healthcare]
Thursday, February 14, 8:23 AM More on Regeneron Pharma (REGN +1.6%) Q4: swings to net profit of $470M from a net loss of $53.4M as sales more than triple, with its Eylea eyecare product bringing in $276M. Earnings also include $127M in collaboration revenues and a non-cash tax benefit of $336M. Forecasts 2013 Eyelea sales of $1.2-1.3B in the U.S. Partner Bayer has started to launch the product overseas. (PR) 1 Comment [Earnings, Healthcare]
Wednesday, January 23, 4:06 AM More on Novartis (NVS) Q4: Chairman Daniel Vasella will resign and will be replaced by senior Bayer health-care executive Joerg Reinhardt, who was formerly COO at Novartis. Provides mid-term guidance for the first time, forecasting mid-single-digit percentage fall in core earnings this year; sales to be in line with 2012, excluding currency swings, although generic competition will eat into revenue by up to $3.5B. Sales growth to resume in 2014 and 2015. Comment! [Earnings, Healthcare]
Sunday, December 9, 2012, 3:28 AM Pfizer's (PFE) and Bristol-Myers Squibb's (BMY) Eliquis blood thinner cut the risk of clots in veins and lungs, and death, by 81% compared with a placebo in major year-long trial. Bleeding was also low. BMY could rack up sales of $4.18B by 2018 if Eliquis is approved - the drug would compete with warfarin, Xarelto from Bayer and J&J (JNJ), and Pradaxa from Boehringer Ingelheim. (PR) 5 Comments [Healthcare, Top Stories]
Tuesday, November 20, 2012, 8:02 AM Bayer (BAYZF.PK) decides to avoid getting enmeshed in a bidding war for Schiff Nutrition (SHF -5.3%), saying it won't increase its $1.2B proposal for the U.S. company after Reckitt Benckiser (RBGPF.PK) offered $1.4B. "Entering a competitive bidding process in response to the November 18 Proposal (Reckitt's bid) would result in a price outside Bayer's set financial criteria," the German drug maker says. Comment! [Healthcare, On the Move, M&A]
Friday, November 16, 2012, 5:14 AM Schiff Nutrition (SHF) shares surged 30% to $44.10 in post-market trading after it became the subject of a bidding war. Reckitt Benckiser (RBGPF.PK) has offered $1.4B, or $42/share, to acquire Schiff, topping a $1.2B proposal from Bayer (BAYZF.PK). Buying Schiff would enable Reckitt to enter the $30B market for vitamins and supplements, a temptation that analysts think could prompt J&J (JNJ) into making a bid as well. Comment! [Financials, Consumer]
Tuesday, October 30, 2012, 4:44 AM Bayer (BAYZF.PK) agrees to acquire Schiff Nutrition (SHF) for $1.2B in cash, with the $34-a-share offer representing a 47% premium to the latter's close on Friday. The deal strengthens Bayer's presence in the U.S., the biggest market in the world for over-the-counter and nutritional products. Separately, Bayer's Q3 EBITDA edges up to €1.85B as sales rise 12% to €9.67B. (PR: merger, earnings) Comment! [Healthcare, M&A]
Monday, August 27, 2012, 9:03 AM The FDA sends Genzyme a "refuse to file" letter in which it asks the Sanofi (SNY) unit to change the presentation of the data in a filing for the firm's Lemtrada treatment for multiple sclerosis so that the application is easier to navigate. The FDA has not requested additional data for further studies for Lemtrada, which could be launched in 2013 if the FDA approves it. (PR) Comment! [Healthcare]
Monday, July 23, 2012, 9:07 AM The combination of Tarceva and Nexavar tablets to treat liver cancer didn't improve survival rates compared with Nexavar on its own in a Phase III trial. Nexavar is jointly produced by Bayer and Onyx (ONXX -0.45%), while Tarceva, which is already used in lung cancer, is sold by Astellas Pharma and Roche unit Genentech. Comment! [Healthcare]
Thursday, June 28, 2012, 3:28 AM The FDA grants priority review to a cancer drug from Onyx Pharmaceuticals (ONXX) and Bayer AG (BAYRY.PK), meaning the FDA will review the drug in six months instead of the standard ten. Regorafenib is meant to treat metastatic colorectal cancer for patients in whom the disease has worsened after standard therapy. Comment! [Healthcare]

BAYZF.PK Bayer Ag Ord

BAYZF.PK

Bayer Ag Ord